S. Jouneau

Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort

Cloé Comarmond, Christian Pagnoux, Mehdi Khellaf et al. · Arthritis & Rheumatism · 2012 · 889 citations

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS

Murielle Grégoire, Fabrice Uhel, Mathieu Lesouhaitier et al. · European Respiratory Journal · 2018 · 206 citations · Full text

Asthma, Ampk Activity, Innate Immune System +16

Incidence of Pneumocystis jiroveci Pneumonia among Groups at Risk in HIV-negative Patients

Pierre Fillâtre, Olivier Decaux, S. Jouneau et al. · The American Journal of Medicine · 2014 · 201 citations · Full text

Clinical Infectious Disease, Pneumocystis Jiroveci Pneumonia, Clinical Epidemiology +7

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease

Alain Lescoat, M Lelong, Mohamed Jeljeli et al. · Biochemical Pharmacology · 2020 · 177 citations

Inflammation, Antifibrotic Therapy, Fibrosis +15